Human CD33 Nanobody for Acute Myeloid Leukemia Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia lack effective targets, as existing therapies do not adequately address the regulation of leukemic cells expressing CD33, a marker highly conserved across malignant myeloid cells.
Innovation Solution
Development of a human CD33 antibody or antigen-binding fragment with specific CDR1, CDR2, and CDR3 sequences, potentially combined with other antigens, to target CD33-expressing cells, including the use of nanobodies for enhanced tumor penetration and stability, and conjugation with therapeutic agents for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody structures are used to target CD33, then antigen binding capability is achieved, but tumor tissue penetrability is limited due to large molecular size
Solution Approach 1:
The patent segments the conventional antibody structure into a single-domain antibody (nanobody) format, retaining only the essential antigen-binding variable domain (VH) while eliminating the constant regions and light chains. This segmentation reduces molecular size from the full antibody structure to approximately 15 kDa, enabling better tumor tissue penetration while preserving CD33 binding capability through optimized CDR regions.
Solution Approach 2:
The invention extracts and isolates the critical antigen-binding function from the complete antibody structure, creating a minimal functional unit consisting of a single VH domain. This extracted nanobody format removes unnecessary structural elements (constant regions, light chains) that impede tissue penetration, while the CDR regions are retained and optimized to maintain high-affinity binding to CD33.
2Length of moving object
If nanobodies are used to enhance tumor penetration, then tissue penetrability is improved, but stability and solubility may be compromised due to reduced molecular structure
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions in the nanobody structure, particularly in the framework regions surrounding the CDRs. These substitutions (such as adding disulfide bonds, optimizing hydrophobic interactions, or modifying surface charges) enhance the thermal stability and solubility of the nanobody, compensating for the reduced structural complexity while maintaining small size for tissue penetration.
3Reliability
If CD33 is targeted in all myeloid cells, then leukemia cells are effectively targeted, but normal hematopoietic cells expressing CD33 may be affected causing off-target toxicity
Solution Approach 1:
The patent creates a composite therapeutic agent by conjugating the CD33-specific nanobody with cytotoxic agents (such as chemotherapy drugs, radioisotopes, or immunocytotoxic compounds). This composite structure enables selective delivery of the toxic payload to CD33-expressing cells. The nanobody component provides high-affinity targeting to CD33 on leukemia cells, while the conjugated therapeutic agent delivers the cytotoxic effect, thereby improving leukemia cell killing while potentially reducing off-target effects through targeted delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody or antigen-binding fragment effectively binds to CD33 with high affinity, potentially inhibiting proliferation and migration of leukemic cells, offering a targeted approach for treating acute myeloid leukemia and related tumors.
Implementation Method 1
The antibody or antigen-binding fragment effectively binds to CD33 with high affinity
Data Source
AI summary
An anti-CD33 antibody and a preparation method therefor and an application thereof. The anti-CD33 antibody has high affinity with CD33 protein, and therefore, can be used for preparation of a drug for treating tumor and the like.